Clinical and demographic data for the 15 participants included in the study.
Participant (gender)
Age at project start ()
Etiology of deafness
Side of implant
Pre/post
Duration of HL ()
eDegree of deafness (dB HL)
Implant type
CI sound processor
CI sound processing strategy
CI 1 (F)
49.8
Cong. non spec.
R
Post
45.8
80–90
Nucleus
Freedom
ACE 900
CI 2 (F)
21.4
Ototoxic
R
Pre
20.7
>90
Nucleus
Freedom
ACE 250
CI 3 (M)
31.7
Meningitis
L
Post
30.2
80–90
Nucleus
Freedom
ACE 900
CI 4 (M)
56.0
Cong. non spec.
R
Post
48.0
80–90
Nucleus
Freedom
ACE 1800
CI 5 (F)
70.3
Cong. non spec.
R
Post
30.3
80–90
Nucleus
Freedom
ACE 900
CI 6 (F)
47.5
Unknown
L
Post
10.5
80–90
Nucleus
Freedom
ACE 1200
CI 7 (F)
56.2
Hered. non spec.
R
Post
37.6
80–90
Nucleus
Freedom
ACE 1200
CI 8 (M)
58.5
Meningitis
R
Pre
53.5
>90
Nucleus
Freedom
ACE 900
CI 9 (F)
29.1
Mon
L
Post
19.1
80–90
Nucleus
Freedom
ACE 1200
CI 10 (F)
44.8
Unknown
R
Post
9.8
80–90
Nucleus
Freedom
ACE 1200
CI 11 (M)
60.4
Unknown
L
Post
16.4
70–90
Nucleus
Freedom
ACE 900
CI 12 (F)
50.6
Cong. non spec.
R
Pre
47.6
>90
A.B.
Harmony
Fid. 120
CI 13 (M)
63.5
Cong. non spec.
L
Pre
57.5
>90
Nucleus
Freedom
ACE 500
CI 14 (F)
63.0
Unknown
R
Post
5.0
70–90
Nucleus
Freedom
ACE 720
CI 15 (M)
73.3
Trauma
R
Post
19.3
70–90
Nucleus
CP 810
ACE 720
Mean
51.8 (SD 15)
29.7
Non specified congenital HL, bnon specified hereditary HL, cMondini dysplasia. dPre- or postlingual HL. eMeasured as the average of pure-tone hearing thresholds at 500, 1000, and 2000 Hz, expressed in dB with reference to normal thresholds. Ranges indicate a difference between left and right ear hearing thresholds. fCochlear, gAdvanced Bionics.
